Catalyst Biosciences (NASDAQ:CBIO)‘s stock had its “buy” rating restated by Chardan Capital in a research report issued to clients and investors on Sunday, AnalystRatings.com reports. They currently have a $25.00 target price on the biopharmaceutical company’s stock. Chardan Capital’s price objective would indicate a potential upside of 338.60% from the stock’s current price.
A number of other research firms have also weighed in on CBIO. Zacks Investment Research lowered Catalyst Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. ValuEngine raised Catalyst Biosciences from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $20.38.
Shares of CBIO traded up $0.14 during midday trading on Friday, hitting $5.70. 72,700 shares of the company traded hands, compared to its average volume of 183,292. The firm has a market cap of $70.05 million, a P/E ratio of -2.13 and a beta of 2.18. Catalyst Biosciences has a one year low of $4.52 and a one year high of $11.29. The company has a debt-to-equity ratio of 0.02, a current ratio of 15.83 and a quick ratio of 15.83. The stock has a 50-day moving average of $5.52 and a 200-day moving average of $7.15.
Catalyst Biosciences (NASDAQ:CBIO) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.01. Sell-side analysts forecast that Catalyst Biosciences will post -4.74 EPS for the current fiscal year.
Hedge funds have recently made changes to their positions in the stock. Essex Woodlands Management Inc. purchased a new stake in Catalyst Biosciences in the second quarter worth $579,000. GSA Capital Partners LLP purchased a new stake in Catalyst Biosciences in the second quarter worth $299,000. Atria Investments LLC purchased a new stake in Catalyst Biosciences in the second quarter worth $176,000. A.R.T. Advisors LLC lifted its stake in Catalyst Biosciences by 16.0% in the second quarter. A.R.T. Advisors LLC now owns 22,828 shares of the biopharmaceutical company’s stock worth $168,000 after acquiring an additional 3,150 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Catalyst Biosciences by 6.0% in the second quarter. Vanguard Group Inc. now owns 592,039 shares of the biopharmaceutical company’s stock worth $4,363,000 after acquiring an additional 33,504 shares during the period. 62.70% of the stock is owned by institutional investors.
Catalyst Biosciences Company Profile
Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.